These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21168197)

  • 21. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
    Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
    Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.
    Endoh H; Yatabe Y; Kosaka T; Kuwano H; Mitsudomi T
    J Thorac Oncol; 2006 Sep; 1(7):629-34. PubMed ID: 17409929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.
    Barault L; Veyrie N; Jooste V; Lecorre D; Chapusot C; Ferraz JM; Lièvre A; Cortet M; Bouvier AM; Rat P; Roignot P; Faivre J; Laurent-Puig P; Piard F
    Int J Cancer; 2008 May; 122(10):2255-9. PubMed ID: 18224685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer.
    Li HT; Lu YY; An YX; Wang X; Zhao QC
    Oncol Rep; 2011 Jun; 25(6):1691-7. PubMed ID: 21424126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. c-KIT Analysis and Targeted Molecular Sequencing of Mesonephric Carcinomas of the Female Genital Tract.
    Pors J; Ho J; Prentice L; Thompson E; Cochrane D; Gibbard E; Huntsman D; Gilks B; Hoang LN
    Am J Surg Pathol; 2020 Apr; 44(4):495-502. PubMed ID: 31714258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
    Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
    J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer.
    Simi L; Pratesi N; Vignoli M; Sestini R; Cianchi F; Valanzano R; Nobili S; Mini E; Pazzagli M; Orlando C
    Am J Clin Pathol; 2008 Aug; 130(2):247-53. PubMed ID: 18628094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer.
    Ikeda Y; Oda K; Nakagawa S; Murayama-Hosokawa S; Yamamoto S; Ishikawa S; Wang L; Takazawa Y; Maeda D; Wada-Hiraike O; Kawana K; Fukayama M; Aburatani H; Yano T; Kozuma S; Taketani Y
    Int J Gynecol Cancer; 2012 Jun; 22(5):725-31. PubMed ID: 22635024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.
    Liu Y; Weber Z; San Lucas FA; Deshpande A; Jakubek YA; Sulaiman R; Fagerness M; Flier N; Sulaiman J; Davis CM; Fowler J; Starks D; Rojas-Espaillat L; Lazar AJ; Davies GE; Ehli EA; Scheet P
    Gynecol Oncol; 2018 Nov; 151(2):243-249. PubMed ID: 30194005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitive genotyping of somatic mutations in the EGFR, KRAS, PIK3CA, BRAF genes from NSCLC patients using hydrogel biochips.
    Emelyanova M; Arkhipova K; Mazurenko N; Chudinov A; Demidova I; Zborovskaya I; Lyubchenko L; Zasedatelev A; Nasedkina T
    Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):255-65. PubMed ID: 25153497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors.
    Wada H; Enomoto T; Fujita M; Yoshino K; Nakashima R; Kurachi H; Haba T; Wakasa K; Shroyer KR; Tsujimoto M; Hongyo T; Nomura T; Murata Y
    Cancer Res; 1997 Dec; 57(23):5379-85. PubMed ID: 9393763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The value of biomarkers in patients with sarcomatoid carcinoma of the lung: molecular analysis of 33 cases.
    Jiang X; Liu Y; Chen C; Zhan Z; Yan Q; Guo Y; Wang Q; Li K
    Clin Lung Cancer; 2012 Jul; 13(4):288-96. PubMed ID: 22169481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival in ampullary cancer: potential role of different KRAS mutations.
    Valsangkar NP; Ingkakul T; Correa-Gallego C; Mino-Kenudson M; Masia R; Lillemoe KD; Fernández-del Castillo C; Warshaw AL; Liss AS; Thayer SP
    Surgery; 2015 Feb; 157(2):260-8. PubMed ID: 25616942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.
    Wang GM; Wong HY; Konishi H; Blair BG; Abukhdeir AM; Gustin JP; Rosen DM; Denmeade SR; Rasheed Z; Matsui W; Garay JP; Mohseni M; Higgins MJ; Cidado J; Jelovac D; Croessmann S; Cochran RL; Karnan S; Konishi Y; Ota A; Hosokawa Y; Argani P; Lauring J; Park BH
    Cancer Res; 2013 Jun; 73(11):3248-61. PubMed ID: 23580570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer.
    Penson RT; Sales E; Sullivan L; Borger DR; Krasner CN; Goodman AK; del Carmen MG; Growdon WB; Schorge JO; Boruta DM; Castro CM; Dizon DS; Birrer MJ
    Gynecol Oncol; 2016 Apr; 141(1):108-12. PubMed ID: 27016236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy.
    Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M
    Anticancer Res; 2013 Apr; 33(4):1705-11. PubMed ID: 23564819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications.
    Kosmidou V; Oikonomou E; Vlassi M; Avlonitis S; Katseli A; Tsipras I; Mourtzoukou D; Kontogeorgos G; Zografos G; Pintzas A
    Hum Mutat; 2014 Mar; 35(3):329-40. PubMed ID: 24352906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.